

PARTICIPATING FACULTY

Hypertension in America: Overcoming Barriers to Blood Pressure Control

This supplement to *The American Journal of Managed Care* is based on presentations at the 2005 American Society of Hypertension scientific meeting and includes information on the prevalence of hypertension in the US population, healthcare costs associated with hypertension, the safety and efficacy of angiotensin receptor blockers in treating hypertension, and factors affecting adherence to hypertension therapy. Genevieve Belgio, a freelance writer and editor, assisted in the writing of this supplement.

Faculty

Vickie Andros, PharmD, *Guest Editor*
Senior Director, Clinical Services
Total Therapeutic Management
Kennesaw, GA

Howard S. Weintraub, MD, *Guest Editor*
Clinical Codirector
Lipid Treatment and Prevention Center
New York University Medical Center
Clinical Assistant Professor of Medicine
New York University School of Medicine
New York, NY

Disclosure Statement

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

The following participant reports relationships with pharmaceutical companies:

■ **Howard S. Weintraub, MD**

Speaker's Bureau For:

AstraZeneca
CV Therapeutics
Novartis
Pfizer
Takeda
Wyeth

The following participant reports no financial affiliations with corporate organizations:

■ **Vickie Andros, PharmD**

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

*Hypertension in America:
Overcoming Barriers to Blood Pressure Control*

EDUCATIONAL OBJECTIVES

After completing this continuing education activity, the participant should be able to:

- Review NHANES data illustrating prevalence of hypertension and rates of hypertension control in the United States.
- Describe barriers to effective hypertension control and discuss strategies for overcoming these barriers.
- Discuss factors influencing patient adherence with hypertension treatment.
- Evaluate the safety and efficacy of angiotensin receptor blockers (ARBs) in treating hypertension and preventing cardiorenal complications.
- Discuss the impact of ARB use on costs of caring for hypertension.

FUNDING

This program is supported by an educational grant from **Novartis Pharmaceuticals**.

• • •

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.